Cumberland Pharmaceuticals (CPIX) closed at $5.30 on November 10, 2026, down 1.3% from the previous close, on volume of 186,922 shares (30-day average 120,146).
Data as of November 10, 2026.
10-Nov-2026
Cumberland Pharmaceuticals GAAP EPS of -$0.07, revenue of $2.16M
Seeking Alpha News (Tue, 10-Nov 5:12 PM ET)
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
PRNewswire (Tue, 10-Nov 4:00 PM ET)
ACCESS Newswire (Thu, 5-Nov 6:15 PM ET)
Business Wire (Thu, 5-Nov 10:53 AM ET)
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS
PRNewswire (Tue, 3-Nov 4:05 PM ET)
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
PRNewswire (Mon, 26-Oct 4:41 PM ET)
Market Chameleon (Mon, 26-Oct 7:04 AM ET)
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
PRNewswire (Fri, 23-Oct 4:12 PM ET)
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
PRNewswire (Fri, 23-Oct 9:06 AM ET)
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
PRNewswire (Mon, 19-Oct 4:07 PM ET)
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Cumberland Pharmaceuticals trades on the NASDAQ stock market under the symbol CPIX.
As of November 10, 2026, CPIX stock price declined to $5.30 with 186,922 million shares trading.
CPIX has a beta of 1.76, meaning it tends to be more sensitive to market movements. CPIX has a correlation of 0.03 to the broad based SPY ETF.
CPIX has a market cap of $79.41 million. This is considered a Micro Cap stock.
In the last 3 years, CPIX traded as high as $9.28 and as low as $1.04.
The top ETF exchange traded funds that CPIX belongs to (by Net Assets): VTI, VXF, DFAS, DFMC, IWC.
CPIX has outperformed the market in the last year with a price return of +219.2% while the SPY ETF gained +12.9%. However, in the short term, CPIX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -32.1% vs -2.8% return in SPY. But in the last 2 weeks, CPIX shares have fared better than the market returning +21.8% compared to SPY -2.0%.
CPIX support price is $4.89 and resistance is $5.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPIX shares will trade within this expected range on the day.
